Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
ICI-ILD
ILA
NSCLC
PD-1 inhibitor
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
18
10
2022
received:
17
09
2022
accepted:
20
10
2022
pubmed:
16
11
2022
medline:
5
1
2023
entrez:
15
11
2022
Statut:
ppublish
Résumé
Interstitial lung abnormalities (ILAs) are known to be a risk of drug-induced pneumonitis. However, there are few reports on the relationship between ILAs and immune checkpoint inhibitor-related interstitial lung disease (ICI-ILD). We retrospectively investigated the clinical significance of ILAs in patients with non-small cell lung cancer (NSCLC) receiving ICIs. We defined ILAs as nondependent abnormalities affecting more than 5% of any lung zone, including ground-glass or diffuse centrilobular nodularities, traction bronchiectasis, honeycombing, and nonemphysematous cysts. Early-onset ICI-ILD was defined as developing within 3 months after the initiation of ICI administration. Of 264 patients with advanced NSCLC, 57 patients (21.6%) had ILAs (43 fibrotic and 14 nonfibrotic ILAs). The difference between the incidence of ICI-ILD in patients with or without ILAs was not significant. Of 193 patients treated by ICI monotherapy, 18 (9.3%) developed early-onset ICI-ILD. Among patients receiving ICI monotherapy, the incidence of early-onset ICI-ILD was significantly higher in patients with than in patients without nonfibrotic ILAs. The presence of nonfibrotic ILAs is a significant risk for early-onset ICI-ILD in patients with NSCLC undergoing ICI monotherapy. Clinicians should be aware of ILAs, especially nonfibrotic ILAs, before administering ICIs to lung cancer patients.
Sections du résumé
BACKGROUND
Interstitial lung abnormalities (ILAs) are known to be a risk of drug-induced pneumonitis. However, there are few reports on the relationship between ILAs and immune checkpoint inhibitor-related interstitial lung disease (ICI-ILD). We retrospectively investigated the clinical significance of ILAs in patients with non-small cell lung cancer (NSCLC) receiving ICIs.
METHODS
We defined ILAs as nondependent abnormalities affecting more than 5% of any lung zone, including ground-glass or diffuse centrilobular nodularities, traction bronchiectasis, honeycombing, and nonemphysematous cysts. Early-onset ICI-ILD was defined as developing within 3 months after the initiation of ICI administration.
RESULTS
Of 264 patients with advanced NSCLC, 57 patients (21.6%) had ILAs (43 fibrotic and 14 nonfibrotic ILAs). The difference between the incidence of ICI-ILD in patients with or without ILAs was not significant. Of 193 patients treated by ICI monotherapy, 18 (9.3%) developed early-onset ICI-ILD. Among patients receiving ICI monotherapy, the incidence of early-onset ICI-ILD was significantly higher in patients with than in patients without nonfibrotic ILAs.
CONCLUSION
The presence of nonfibrotic ILAs is a significant risk for early-onset ICI-ILD in patients with NSCLC undergoing ICI monotherapy. Clinicians should be aware of ILAs, especially nonfibrotic ILAs, before administering ICIs to lung cancer patients.
Identifiants
pubmed: 36377039
doi: 10.1111/1759-7714.14718
pmc: PMC9807441
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-80Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Respirology. 2009 Jul;14(5):723-8
pubmed: 19659650
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Front Oncol. 2020 Sep 11;10:1785
pubmed: 33042827
JAMA. 2016 Feb 16;315(7):672-81
pubmed: 26881370
Eur Respir J. 2017 Aug 10;50(2):
pubmed: 28798088
Am J Respir Crit Care Med. 2000 Jan;161(1):5-8
pubmed: 10619790
Clin Cancer Res. 2016 Dec 15;22(24):6051-6060
pubmed: 27535979
JAMA Netw Open. 2020 Nov 2;3(11):e2022906
pubmed: 33180128
Cancer Immunol Res. 2016 Apr;4(4):289-93
pubmed: 26865455
Respiration. 2004 Jul-Aug;71(4):301-26
pubmed: 15316202
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Thorac Cancer. 2018 Jul;9(7):847-855
pubmed: 29782069
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Clin Oncol. 2017 Mar;35(7):709-717
pubmed: 27646942
Lung Cancer. 2018 Nov;125:212-217
pubmed: 30429022
Thorac Cancer. 2023 Jan;14(1):73-80
pubmed: 36377039
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Am J Respir Crit Care Med. 2019 Jul 15;200(2):175-183
pubmed: 30673508
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Lancet Respir Med. 2020 Jul;8(7):726-737
pubmed: 32649920
Radiology. 2019 Apr;291(1):1-3
pubmed: 30561274
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer Chemother Pharmacol. 2018 Jan;81(1):131-139
pubmed: 29143072
N Engl J Med. 2015 Jul 16;373(3):288-90
pubmed: 26176400
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Invest New Drugs. 2021 Aug;39(4):1150-1158
pubmed: 33483882
Radiology. 2019 Aug;292(2):489-498
pubmed: 31161974
Eur J Radiol. 2015 May;84(5):998-1004
pubmed: 25726730
Respir Investig. 2019 Sep;57(5):451-459
pubmed: 31248832